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Purpose
Interstitial granulomatous dermatitis (IGD) has been
reported in association with autoimmune disorders in
adults. These associated conditions include rheumatoid
arthritis, seronegative arthritis, SLE, autoimmune thyroidi-
tis and others. It has also been described in drug-reaction
pulmonary coccidioidomycosis, Lyme’s disease and pul-
monary silicosis. IGD has rarely been described in
children.
Methods
A thirteen-year old white male presented with anorexia,
fever (104oF) and joint pains involving his ankles, knees,
elbows and shoulders. He developed multiple erythema-
tous, plaques on chest and back. The patient was initially
treated with prednisone, and the rash and joint symptoms
resolved but recurred repeatedly. The rash was erythema-
tous, slightly raised, tender for about 3 days, became
ecchymotic and then gradually faded away in 7-10 days.
The majority of the lesions were distributed on trunk and
axilla. The lesions were non-pruritic, papular or annular in
character and tended to migrate from one location to
another.
Microscopically, the lesion showed diffuse infiltration of
the dermis and upper subcutaneous fat by mononuclear
cells. The infiltrate had a perivascular and diffuse pattern
and it splayed the pre-existing collagen fibers and
extended to superficial fat, where it assumed a lobular pat-
tern. Churg-Strauss granulomas were present, comprised
of degenerated collagen foci with surrounding accumula-
tion of histiocytes. Mild mucin accumulation was seen.
The pattern was felt to be compatible with IGD.
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Immune work-up revealed the following: FANA- 1:1280;
anti-nRNP 1:512; with negative anti-dsDNA, anti-Sm.,
anti-Scl70, anti-SSA/B, and anti-centromere antibodies.
ANCA was negative. CPK was elevated at height of muscle
weakness at 840 IU (NR <200) while Aldolase was 24.0 u/l
(NR < 8.3 u/l). Studies for infectious etiology were
negative.
Results
Although the patient’s symptoms responded to oral pre-
dnisone, his symptoms returned as steroid therapy was
withheld. Immunosuppressive agents such as methotrex-
ate and cyclosporine were ineffective in controlling the
disease but responsive to tacrolimus was dramatic and
sustained.
Conclusion
IGD is an uncommon dermatologic manifestation of
pediatric rheumatic diseases. This case is a first description
of its occurrence in childhood mixed connective disease
and pediatric rheumatology community should be aware
of its presentation. The response of IGD to tacrolimus in
this patient may reflect the underlying immunopathogen-
esis of IGD. Further, tacrolimus should be considered in
recalcitrant cases of IGD.
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